

eTable 2. Patient characteristics following the first positive SARS-CoV-2 test, by value of first aldosterone thereafter.

Characteristic	Aldosterone ≤ 70 pmol/L	Aldosterone > 70 pmol/L	p-value¹
Sample size (<i>n</i>)	74	52	
Age at admission, median [IQR] (% missing)	64 [48.25, 82] (0%)	58 [41, 77] (0%)	0.28
Gender (male), <i>n</i> (%)	43 (58.1%)	30 (57.7%)	~1
<i>Ethnicity, n (%)</i>			
White	46 (62.2%)	36 (69.2%)	0.529
Black	1 (1.4%)	0 (0%)	~1
Asian	9 (12.2%)	4 (7.7%)	0.607
Other	2 (2.7%)	1 (1.9%)	~1
Not specified/prefer not to say	16 (21.6%)	11 (21.2%)	~1
Body mass index, median [IQR] (% missing), kg/m	25.4 [23.2, 29.6] (9.5%)	28.6 [24.75, 32.85] (9.6%)	0.14
<i>Observations, median [IQR] (% missing)</i>			
Heart rate, beats/min	85 [75, 96] (1.4%)	88 [77, 95] (0%)	0.61
Temperature, °C	37.4 [36.8, 38.1] (0%)	37.1 [36.7, 37.7] (0%)	0.75
Respiratory rate, breaths/min	19 [17, 22] (0%)	18 [17, 20] (0%)	0.058

Oxygen saturation (SpO ₂), %	95 [94, 97] (1.4%)	96 [94, 97] (0%)	0.40
Mean arterial pressure, mmHg	90 [80, 100] (0%)	91 [83, 97] (0%)	0.11
Blood tests, median [IQR] (% missing)			
C-reactive protein, mg/L	54 [26, 114] (2.7%)	39 [25, 77] (5.8%)	0.45
White cell count, 10 ⁹ /L	5.9 [4.8, 6.8] (2.7%)	5.3 [4.4, 7.1] (1.9%)	0.85
Sodium, mmol/L	136 [134, 139] (4.1%)	137 [134, 139] (5.8%)	0.89
Potassium, mmol/L	4.0 [3.8, 4.3] (1.5%)	4.1 [3.7, 4.6] (1.5%)	0.13
Neutrophils, 10 ⁹ /L	4.3 [3.2, 5.4] (2.7%)	3.8 [2.6, 5.5] (1.9%)	0.34
Lymphocytes, 10 ⁹ /L	0.84 [0.55, 1.12] (2.7%)	1.07 [0.71, 1.61] (1.9%)	0.44
Interleukin-6, pg/ml	9.5 [5.73, 20.89] (59.5%)	7.15 [3.86, 13.16] (50%)	0.40
Urea, mmol/L	5.4 [3.7, 8.5] (10.8%)	5.9 [4.4, 7.3] (15.4%)	0.56
Creatinine, μ mol/L	72 [59, 89] (4.1%)	76 [64, 88] (3.8%)	0.92
D-Dimer, ng/ml	233 [176, 373] (41.9%)	205 [155, 362] (50%)	0.37
Troponin, ng/L	9 [3.1, 32.9] (41.9%)	4 [3, 7.5] (40.4%)	0.95
pH value	7.41 [7.38, 7.44] (39.2%)	7.4 [7.37, 7.44] (30.8%)	0.94
Medical history², n (%)			
Heart disease	12 (16.2%)	9 (17.3%)	~1

Hypertension	23 (31.1%)	12 (23.1%)	0.43
Beta blockers at admission ³	6 (8.1%)	3 (5.75%)	0.88
Diabetes	19 (25.7%)	10 (19.2%)	0.53
Endocrine disease (other than diabetes)	7 (9.5%)	6 (11.5%)	0.94
Stroke	2 (2.7%)	1 (1.9%)	~1
Dementia	5 (6.8%)	2 (3.8%)	0.76
Asthma	6 (8.1%)	8 (15.4%)	0.32
Respiratory disease (other than asthma)	8 (10.8%)	5 (9.6%)	~1
Chronic kidney disease	4 (5.4%)	2 (3.8%)	~1
Chronic liver disease	4 (5.4%)	4 (7.7%)	0.88
Malignancy non-haematological	13 (17.6%)	3 (5.8%)	0.092
Malignancy haematological	4 (5.4%)	0 (0%)	0.24
Immunocompromised	2 (2.7%)	0 (0%)	0.64
<i>Treatments and outcomes, n (%)</i>			
In-hospital deaths	10 (13.5%)	6 (11.5%)	0.96
Admitted to ICU	9 (12.2%)	7 (13.5%)	0.96
Invasive mechanical	7 (9.5%)	7 (13.5%)	0.68

ventilation			
Renal replacement therapy	6 (8.1%)	4 (7.7%)	~1

¹Mood's test for median values, Chi-squared test for categorical data

²See eTable 3 for ICD-10 code lists

³Bisoprolol, Atenolol, Propranolol, Carvedilol.

